December 12, 2018 6:07pm

Investors NEED to base their investment decisions on interpreted “intel” and be aware of the “warning” analysis by RMi to “grasp” the minutia of sector and session moves.

I’d be reaping upside profits!


Out and about: Biogen (BIIB) terminated their collaboration with Applied Genetic Technologies Corporation (AGTC) while reporting topline interim six-month data from its P1/2 clinical trial of rAAV2tYF-CB-hRS1 showing that rAAV2tYF-CB-hRS1 is generally safe and well-tolerated, but NO signs of clinical activity were observed at six-months. AGTC dropped -$2.41 or -36.74% in the aftermarket.


Pre-open indications: 2 HITs and 1 MISS

Investors should be reading about today’s final “figures” – be a subscriber and be ready for tomorrow’s session! As I have stated … today’s gold could be tomorrow’s tin!

Members only. Please login.